ORIGINAL ARTICLE



Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients : A meta-analysis

Johanes Nugroho^{1,2} | Ardyan Wardhana³ | Irma Maghfirah² | Eka Prasetya Budi Mulia² | Dita Aulia Rachmi² | Maya Qurota A'yun² | Imanita Septianda²

Correspondence

Johanes Nugroho, Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga, Dr. Soetomo General Hospital, Surabaya, 60285, Indonesia.

Email: j.nugroho.eko@fk.unair.ac.id

Abstract

Introduction: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic. Many studies have shown that several laboratory parameters are related to disease severity and mortality in SARS-CoV-2 cases. This meta-analysis aimed to determine the relationship of a prognostic factor, D-dimer, with disease severity, need for intensive care unit (ICU) care, and mortality in SARS-CoV-2 patients.

Methods: A systematic search for all observational studies and trials involving adult patients with SARS-CoV-2 that had any data related to D-dimer on admission was conducted using PubMed, Science Direct, Scopus, ProQuest, and MedRxiv databases. We performed random-effects inverse-variance weighting analysis using mean difference (MD) of D-dimer values for outcomes such as disease severity, mortality, and need for ICU care.

Results: A total of 29 studies (4,328 patients) were included in this meta-analysis, which revealed a higher mean of D-dimer levels on admission in severe patients than in nonsevere patients (MD = 0.95, [95% confidence interval (CI): 0.61-1.28], P < .05; $I^2 = 90\%$). The nonsurvivor group had a higher pooled MD of D-dimer values on admission (MD = 5.54 [95% CI: 3.40-7.67], P < .05; $I^2 = 90\%$). Patients who needed ICU admission had insignificantly higher D-dimer values than patients who did not need ICU admission (MD = 0.29, [95% CI: -0.05 to 0.63], P = .10; $I^2 = 71\%$).

Conclusion: Elevated D-dimer levels on admission were associated with an increased risk of disease severity and mortality in patients with SARS-CoV-2 infection.

KEYWORDS

D-dimer, laboratory, mortality, prognostic factor, SARS-CoV-2, severity

1 | INTRODUCTION

A new viral pneumonia was first detected in Wuhan, China, and was found to be caused by a novel coronavirus, later identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that has since then caused a pandemic. Previous reports have shown that certain laboratory parameters correlated with disease

severity and mortality in SARS-CoV-2 infection.¹ The levels of D-dimer, an important prognostic factor, were found to be higher in patients with a clinically severe case of SARS-CoV-2 than in nonsevere cases.² A better understanding of this prognostic factor can help physicians predict the disease severity and need for intensive care unit (ICU) care in patients infected with SARS-CoV-2. This meta-analysis aimed to determine the relationship

Int J Lab Hematol. 2020;00:1–6. wileyonlinelibrary.com/journal/ijlh © 2020 John Wiley & Sons Ltd 1

¹Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

²Dr. Soetomo General Hospital, Surabaya, Indonesia

³Faculty of Medicine, Universitas Surabaya, Surabaya, Indonesia

of D-dimer with disease severity and mortality in SARS-CoV-2 patients.

2 | METHODS

We conducted this study following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We selected all observational studies and trials involving adult patients with SARS-CoV-2 that had any data on D-dimer values for comparing different groups: severe vs. nonsevere; ICU vs. non-ICU; survivor vs. nonsurvivor. We excluded any study that did not have the required data, collect D-dimer data on admission, and report D-dimer data in numerical values.

A systematic literature search was carried out after receiving approval from the Institutional Review Board. Five different databases (PubMed, Science Direct, Scopus, ProQuest, and MedRxiv) were used to perform a systematic search of all the literature using the keywords "intensive" and "laboratory" and "COVID-19" or "coronavirus 2019" or "2019-nCoV" or "SARS-CoV-2," in the title, abstract, and medical subject heading (MeSH). We used "laboratory" as a search term instead of D-dimer because earlier studies did not consider D-dimer as an important factor, and hence, this factor was reported as data related to the laboratory report on admission. D-dimer levels were neither mentioned nor discussed separately in these reports. The reference lists of the studies included were screened to identify additional studies relevant to D-dimer.

Three investigators independently screened and assessed titles and abstracts before full-text retrieval. The other two authors reviewed the papers for final inclusion and extracted data including authors, year of publication, location, study design, peer-reviewed publication status, disease severity measurement, and D-dimer levels in each comparison group.

The primary outcome in our meta-analysis was the D-dimer levels on admission based on the severity of the case. We used all definition of severity. If the study categorized disease severity into three or four groups, we combined all the data found in the mild and moderate group into one group as nonsevere; severe and critical groups were combined into one group as severe. The average of their mean and standard deviation was calculated using the formula in Table 7.7.a of the Cochrane Handbook.³ The secondary outcomes were D-dimer levels on admission based on mortality and intensive care need.

Two authors independently assessed the methodological quality assessment using the National Heart Lung and Blood Institute Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. We conducted the meta-analysis using the mean difference (MD) for D-dimer levels. Mean and standard deviation values were extrapolated from the sample size, median, and interquartile range (IQR), according to Wan et al⁴ We employed a fixed-effects and inverse-variance weighting using Review Manager (RevMan v5.3 2014). We carried out a subgroup analysis based on study design. We performed a sensitivity analysis based on peer

review and age difference status. We evaluated inter- and intrastudy heterogeneity using the I^2 statistic. We applied a random-effects meta-analysis if the heterogeneity is significant.

3 | RESULT

We identified a total of 111 records from the PubMed database, 488 records from the ScienceDirect database, 20 records from the ProQuest database, 42 records from the Scopus database, 846 records from the MedRxiv database, and 127 records from other sources as shown in Figure 1. One-hundred and fifty-one other studies were excluded because of incorrect population (4 studies), irrelevant exposure (83 studies), irrelevant outcome (42 studies), study not reported in English (1 study), D-dimer values not collected on admission (9 studies), and irrelevant severity criteria (12 studies). We excluded the study of Levy et al from our analysis because D-dimer measurements were missing in 78% of the patients and there was no information regarding the proportion of those missing in each group. Twenty-nine studies (4,328 patients) were included in the analysis. 6-34

The baseline characteristics of the included studies are presented in Supplementary file 1. Twenty-six studies were retrospective, and three studies were prospective observational. Fifteen studies have already undergone peer review. ^{6,12,14,16,18-21,24,25,27,30,31,33,34} One study provided a comparison between groups for disease severity and mortality. ¹¹ Most of the studies classified the disease severity according to the National Health Commission of the People's Republic of China. Only three studies considered subjects of similar age in both groups. ^{28,30,33}

Among the 29 studies included in this meta-analysis, most did not identify whether D-dimer values were reported as D-dimer units (DDU) or fibrinogen equivalent units (FEU). Only 3 studies clearly stated using FEU. ^{20,22,30} Nine studies did not report the normal cutoff value of D-dimer (Supplementary file 1).

We assessed all studies wherein all outcomes were obtained using a good and fair methodology (Supplementary file 1). None of the studies that were considered had any flaws in the analyses. The analyses were rigorous, and the conclusions drawn by the studies were credible. However, most studies did not assess exposure prior to outcome measurement and may have lacked sufficient timeframe for the outcomes to occur because of their cross-sectional design.

Random-effects meta-analysis revealed a higher mean of D-dimer levels on admission in severe patients than in nonsevere patients as shown in Table 1 (14 studies, MD = 0.95, [95% CI: 0.61-1.28], P < .05; $I^2 = 90\%$). Subgroup analysis based on the study design showed a similar result in both subgroups. Sensitivity analysis based on the peer-reviewed status from 6 studies showed an MD of 0.68 with 95% CI 0.26-1.10 and $I^2 = 86\%$ (Supplementary file 2).

Nonsurvivor group had a pooled higher mean difference of D-dimer values on admission as shown in Table 1 (9 studies, MD = 5.54 [95% CI: 3.40-7.67], P < .05; $I^2 = 90\%$) than survivor groups. Sensitivity analysis showed similar result (5 studies,




FIGURE 1 Study flow chart (as per PRISMA guideline)

MD = 5.78, [95% CI: 2.94-8.63], P < .05; $I^2 = 84\%$) when we excluded nonpeer-reviewed studies. We did not perform a subgroup analysis based on study design because all included studies were retrospective observational.

Patients with need for ICU care had higher D-dimer values on admission than patients who did not need ICU care (seven studies, MD = 0.29, [95% CI: -0.05 to 0.63], P = .10; $I^2 = 71\%$) as shown in Table 1. Sensitivity analysis showed a similar result when we excluded studies that had significant age differences pertaining to participants estimates (3 studies, MD = 4.35, [95% CI: -2.31 to 11.01], P = .20; $I^2 = 81\%$). However, the effect estimates changed and were

found to be significant without improvement in heterogeneity (4 studies, MD = 0.48, [95% CI: 0.21-0.76], P < .05; $I^2 = 66\%$) when we excluded nonpeer-reviewed studies.

4 | DISCUSSION

This meta-analysis showed that increasing D-dimer levels on admission were significantly associated with increased disease severity and mortality. The results obtained were similar to the results reported previously in two other systematic reviews. 35,36 Pooled

TABLE 1 Summary of findings

Outcomes	Studies	Participants	Effect Estimates	Р	12
Severity	14	2190	0.95 [0.61, 1.28]	<.05	90%
Retrospective	11	1557	1.30 [0.78, 1.82]	<.05	91%
Prospective	3	633	0.54 [0.05, 1.04]	<.05	90%
Sensitivity analysis	6	775	0.29 [-0.05, 0.63]	<.05	86%
Mortality	9	1808	5.54 [3.40, 7.67]	<.05	90%
Sensitivity analysis ^a	5	851	5.78 [2.94, 8.63]	<.05	84%
Needs of ICU	7	657	0.29 [-0.05, 0.63]	.1	71%
Sensitivity analysis ^a	4	241	0.48 [0.21, 0.76]	<.05	66%
Sensitivity analysis ^b	3	89	4.35 [-2.31, 11.01]	.2	81%

^aSensitivity analysis based on peer-reviewed status.

analysis by Shah et al demonstrated that patients who had D-dimer levels more than 0.5 mg/L had a twofold higher risk of developing a severe case of the disease and fourfold higher risk of mortality than those who had D-dimer levels less than 0.5 mg/L. 36 Higher cutoff value of D-dimer (>2 mg?L) was considered to be even better in predicting in-hospital mortality in SARS-CoV-2 with a sensitivity of 92.3% and a specificity of 83.3% after adjusting for age, gender, and comorbidities. 37

Our study also showed that patients with a need for ICU care had nonsignificant higher D-dimer values on admission than patients who did not need ICU care. An earlier study demonstrated that there was an increased incidence of thrombotic complications in patients treated in the ICU. ³⁸ Hypercoagulability state was also found in patients admitted to ICU where D-dimer levels were drastically increased. ³⁹ At the late stages of SARS-CoV-2, levels of fibrin-related markers (D-dimer and fibrin degradation product) were either moderately or markedly elevated in all cases of death suggesting a common coagulation activation and secondary hyperfibrinolysis condition in these patients. ²⁴

Histopathology studies on the lung biopsy of critical patients with SARS-CoV-2 revealed the presence of occlusion and microthrombosis formation in pulmonary small vessels. 40 The exact mechanism responsible for coagulopathy in SARS-CoV-2 patients is not yet identified. Whether SARS-CoV-2 can directly attack vascular endothelial cells expressing high levels of angiotensin-converting enzyme 2 (ACE2) leading to abnormal coagulation and sepsis is an aspect that still needs to be explored.

Our meta-analysis suggests that elevated D-dimer levels can be a marker of poor prognosis in patients with coronavirus disease (COVID-19). During a pandemic, risk stratification in triage is necessary, and D-dimer can be one of the potential indicators in the case of high-risk patients. However, only the presence of elevated D-dimer only is not a reason enough to start the administration of therapeutic anticoagulants.

To the best of our knowledge, this meta-analysis conducted using 29 different studies is the largest that evaluates the prognostic role of D-dimer on admission in SARS-CoV-2 patients. However, several limitations should be noted in our study. First, there was substantial heterogeneity across studies. Most of the studies included were retrospective with relatively small sample size. Second, the variation in reporting the unit of D-dimer inevitably might affect our interpretation and analysis of the D-dimer data. Third, the analysis in this study was performed during the pandemic; researchers conducting studies in many areas affected by SARS-CoV-2 have not published their data as yet. Most of the studies included were from mainland China, while the remaining three studies were from the USA. Ethnic and geographical differences could distort the results of the analysis.

5 | CONCLUSIONS

Our meta-analysis demonstrated that elevated D-dimer levels on admission were associated with an increased risk of disease severity and mortality in SARS-CoV-2 infection.

ACKNOWLEDGEMENT

This work did not receive specific funding, but was performed as part of 2ohanes Nugroho employment at the Department of Cardiology and Vascular Medicine, Universitas Airlangga 2Dr Soetomo 2 eneral Hospital, East 2ava, Indonesia.

^bSensitivity analysis based on age difference status.

CONFLICT OF INTEREST

(If present, give more details): The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be considered as a potential conflict of interests.

AUTHOR CONTRIBUTIONS

Involved in conceptualization, methodology, writing-review and editing, and supervision. AW involved in conceptualization, data analysis, manuscript writing-review and editing. IM involved in screening, data extraction, investigation, data analysis, and writing-original draft. EM involved in screening, data extraction, investigation, and writing-original draft. MA involved in screening, investigation, data extraction, writing-original draft, and project administration. DR and IS involved in investigation, data analysis, quality assessment, and writing-original draft.

IEC APPROVAL

Dr Soetomo 🛚 eneral Hospital Surabaya Ethical Committee in Health Research (0005/LOE/301A.2/05/2020).

TRIAL REGISTRY

UMIN Clinical Trial Registry (UMIN ID 000 040 433).

DATA AVAILABILITY STATEMENT

The data supporting this meta-analysis are from previously reported studies and data sets, which have been cited.

ORCID

Johanes Nugroho https://orcid.org/0000-0002-3501-1872

Ardyan Wardhana https://orcid.org/0000-0003-4048-2414

REFERENCES

- 1. Han H, ②ang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;③② cclm.ahead-of-print/cclm-2020-0188/cclm-2020-0188.xml
- 2. Mattiuzzi C, Lippi 2. Which lessons shall we learn from the 2019 novel coronavirus outbreak Ann Transl Med. 2020;8:48.
- 3. Higgins PT, Preen S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration; 2011 [cited 2020 May 10]. Available from: https://handbook-5-1.cochrane.org?
- 4. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and or interquartile range. BMC Med Res Methodol. 2014;14(1):1-13.
- Levy TJ, Richardson S, Coppa K, et al. Estimating survival of hospitalized COVID-19 patients from admission information. *medRxiv*. 2020;2020.04.22.20075416.
- Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020. https://doi.org/10.1111/all.14309
- Chen X, Zheng F, Qing Y, et al. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. *medRxiv* 2020;2020.03.03.20030353.
- 8. Han Y, Zhang H, Mu S, et al. Lactate dehydrogenase, a risk factor of severe COVID-19 patients: a retrospective and observational study. *medRxiv* 2020;2020.03.24.20040162.

- 9. Li Z, Wu M, Yao J, et al. Caution on kidney dysfunctions of COVID-19 patients. *medRxiv*. 2020;2020.02.08.20021212.
- Liu L, Gao J. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. medRxiv. 2020;;2020.02.20.20025536.
- Luo X, Xia H, Yang W, et al. Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan, China. *medRxiv*. 2020;2020.03.19.20033175.
- 12. Qian 2 -Q., 2 ang N-B, Ding F, et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM. 2020;113(7):474-481
- 13. Shi P, Ren 2, 2ang 2, et al. Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: a multicenter retrospective study. *medRxiv*. 2020;2020.04.19.20071472.
- Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan. China. J Clin Virol. 2020;127:104364.
- Zhang H, Wang X, Fu Z, et al. Potential factors for prediction of disease severity of COVID-19 patients. *medRxiv*. 2020;2020.03.20.20039818.
- Zhang J-J, Dong X, Cao Y-Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan China. Allergy. 2020;75:1730-1741.
- 17. Zhou Y, Yang Z, Guo Y, et al. A new predictor of disease severity in patients with COVID-19 in Wuhan, China. *medRxiv*. 2020;2020.03.24.20042119.
- Chen G, Wu DI, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620-2629.
- 19. Sun ②, Dong ②, Wang L, et al. Characteristics and prognostic factors of disease severity in patients with COVID-19: the Beijing experience. *J Autoimmun*. 2020;112:102473.
- 20. ②an ②, ③ang ②, Wang F, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. *BMJ Open Diabetes Res Care*. 2020;8:e001343.
- Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020:368:m1091.
- Chen X, Liu Z. Early prediction of mortality risk among severe COVID-19 patients using machine learning. *medRxiv*. 2020:2020.04.13.20064329.
- 23. Paranjpe I, Russak A, De Freitas JK, et al. Clinical characteristics of hospitalized Covid-19 patients in New ②ork City. *medRxiv*. 2020;2020.04.19.20062117.
- 24. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(4):844-847.
- Tu WJ, Cao J, Yu L, Hu X, Liu Q. Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan. *Intensive Care Med.* 2020;1–4.
- 26. Zhang F, Yang D, Li J, et al. Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: a single center retrospective cohort study. *medRxiv*. 2020;2020.03.21.20040121.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. *Lancet*. 2020;395:1054-1062.
- 28. Lau FH, Majumder R, Torabi R, et al. Vitamin D insufficiency is prevalent in severe COVID-19. *medRxiv*. 2020;2020.04.24.20075838.
- 29. Zhou J, Sun J, Cao Z, Wang W, Huang K, Zheng F, et al. Epidemiological and clinical features of 201 COVID-19 patients in Changsha, China. Res Sq. 16 March 2020, Preprint 2020;(version 1). https: ☑ doi.org/10.21203/rs.3.rs-17313/v1
- 30. Wang F, Yang Y, Dong K, et al. Clinical characteristics of 28 patients with diabetes and Covid-19 in Wuhan, China. *Endocr Pract.* 2020.



- 31. Lei S, ②ang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. *EClinicalMedicine*. 2020;100331.
- 32. Cao M, Zhang D, Wang Y, et al. Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai China. *medRxiv*. 2020;2020.03.04.20030395.
- 33. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. *Lancet*. 2020;395:497-506.
- 34. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069.
- 35. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019: a pooled analysis [Letter to Editor]. *Thromb Haemost*. 2020;120(05):876-878.
- Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: A systematic review and meta-analysis. medRxiv. 2020;2020.04.29.20085407.
- 37. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 [published online ahead of print, 2020 Apr 19]. *J Thromb Haemost*. 2020. https://doi.org/10.1111/jth.14859
- Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;S0049-3848(20)30120-1.

- 39. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. *J Thromb Haemost*. 2020. https://doi.org/10.1111/jth.14850
- Luo W, Yu H, Gou J, et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID 19). Preprints. 2020;2020020407. https://doi.org/10.20944/preprints202004. 0004.v1

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Nugroho ② Wardhana A, Maghfirah I, et al. Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients: A meta-analysis. *Int J Lab Hematol*. 2020;00:1②6. https:@doi.org@10.1111@jlh.13336



formerly Clinical & Laboratory Haematology

The Official journal of the International Society for Laboratory Hematology

COVID-19 coagulopathy

Impact of DOACs on thrombophilia tests

Morphology EQAS in Spain

ISLH

ISSN 1751-5521

ISSN 1751-553X (Online)

Volume 43

Number 1

February 2021

www.ijlh.com

WILEY

International Journal of Laboratory Hematology

The Official journal of the International Society for Laboratory Hematology



Editorial Board

Editors-in-Chief

Ian Mackie, *University College London, London, UK*Giuseppe d'Onofrio, *Catholic University of Rome, Rome, Italy*

Associate Editors

Anthony Bench, Western General Hospital, Edinburgh, UK
Katrien Devreese, Ghent University Hospital, Belgium
John L. Frater, Washington University, USA
Jin-Yeong Han, Dong-A University College of Medicine, Busan, Korea
Cornelis Harteveld, Leiden University Medical Centre, Leiden, Netherlands
Qian-Yun Zhang, University of New Mexico, Albuquerque, USA

Past Editors

T. George

S-H. Lee

S. Kitchen

W. Finn

S. Bentley

I. Cavill

J. M. England (Founding Editor)

Editorial Board

Anni Aggerholm, *Denmark*Maher Albitar, *USA*Erik Amundsen, *Norway*Martin Besser, *UK*Gini Bourner, *Canada*Mauro Buttarello, *Italy*Sung-Ran Cho, *Korea*David Czuchlewski, *USA*Barbara de la Salle, *UK*Anne Deucher, *USA*Charles Eby, *USA*Mariela Granero Farias, *Brazil*Emmanuel Favaloro, *Australia*

1 of 5 4/22/2022, 10:37 AM

Will Finn, USA Supan Fucharoen, Thailand Tracy George, USA Robert C. Gosselin, USA Catherine Hayward, Canada James Hoyer, USA Albert Huisman, Netherlands Surender Juneja, Australia Steve Kitchen, UK Alexander Kratz, USA Szu-Hee Lee, Australia Jean-Francois Leseve, France Marta Martinuzzo, Argentina Anna Merino, Spain Olga Pozdnyakova, USA Maria Proytcheva, USA Joyce Rogers, USA Margreet Schoorl, Netherlands Kristi Smock, USA Hongwei Wang, China Olga Weinberg, USA Gina Zini, *Italy*

ISLH Board of Directors

Executive Committee

Tracy George, *Utah*, *USA* (President)
Catherine Hayward, *Ontario*, *Canada* (*Past-President*)
Katrien Devreese, *Ghent*, *Belgium* (*Treasurer*)
Ruth Padmore, *Ontario*, *Canada* (*VP of Education*)
John Frater, *St. Louis*, *USA* (*Vice President for Scientific Communications*)
Karen Moffat, *Ontario*, *Canada* (*Vice President for Membership*)
Giuseppe d'Onofrio, *Rome*, *Italy* (*Editor-in-Chief*, *International Journal of Laboratory Hematology*)
lan Mackie, *London*, *UK* (*Editor-in-Chief*, *International Journal of Laboratory Hematology*)

Members of the Board

Marie-Christine Bene, France
Deepak Mishra, India
Parul Bhargava, USA
Anna Ruskova, New Zealand
Archana Agarwal, USA
Olga Weinberg, USA
Barbara De La Salle, UK
Qian-Yun Zhang, USA
Jin-Yeong Han, Korea
Pierre Toulon, France

2 of 5 4/22/2022, 10:37 AM

Councilors

Ilknur Kozanoglu, Turkey Samia Rizk, Egypt Martha Eva Viveros, Mexico Saleem Ahmed Khan, Pakistan Glenda Davison, South Africa Swati Pai, India Cheng-Bin Wang, China Simon Onsongo, Kenya Yutaka Yatomi, Japan Seongsoo Jang, Korea Alex Freire Sandes, Brazil Mimi Azura Binti Aziz, Malaysia

Executive Director
Adam Kohm, Glenview, USA

Editorial Office

Email: <u>IJLHoffice@wiley.com</u>

Tools

- Submit an Article
- **B**rowse free sample issue
- Get content alerts
- Subscribe to this journal

International Society of Laboratory Hematology



More from this journal

3 of 5 4/22/2022, 10:37 AM

International Journal of Laboratory Hematology

The Official journal of the International Society for Laboratory Hematology



Volume 43, Issue 1

Pages: i-iv, 1-142, e1-e53

February 2021

« Previous Issue | Next Issue »

≔ GO TO SECTION

** Export Citation(s)

ISSUE INFORMATION

ரி Free Access

Issue Information Covers

Pages: i-iv | First Published: 19 January 2021

First Page | PDF | Request permissions

Free Access

Issue Information - TOC

Pages: 1-2 | First Published: 19 January 2021

PDF | Request permissions

CASE IMAGES

Pseudo-Pelger-Huët anomaly in a 58-year-old woman treated with mycophenolate

mofetil for flare of systemic lupus erythematosus

Yue Zhao, Catherine Rehder, Endi Wang

Pages: 3-4 | First Published: 18 November 2020

Full text | PDF | References | Request permissions

Acute lymphoblastic leukaemia in a child with hereditary elliptocytosis

Peng Sun, Rong Wen, Xiangmao Bu, Wenjie Li, Wenfeng Mu

Pages: 5-6 | First Published: 24 November 2020

Full text | PDF | References | Request permissions

REVIEWS

ரி Free Access

Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory

Romain Siriez, Jean-Michel Dogné, Robert Gosselin, Julie Laloy, François Mullier, Jonathan Douxfils

Pages: 7-20 | First Published: 18 September 2020

Abstract | Full text | PDF | References | Request permissions

☆ Free Access

Standardization of Prothrombin Time/International Normalized Ratio (PT/INR)

Akbar Dorgalaleh, Emmanuel J. Favaloro, Mehran Bahraini, Fariba Rad

Pages: 21-28 | First Published: 26 September 2020

Abstract | Full text | PDF | References | Request permissions

ORIGINAL ARTICLES

Cell Counting/Automation

⊡ Open Access

The Sysmex XN-L (XN-350) hematology analyzer offers a compact solution for laboratories in niche diagnostics

Tania A. Khartabil, Magda M. de Frankrijker, Yolanda B. de Rijke, Henk Russcher

Pages: 29-39 | First Published: 19 September 2020

Abstract | Full text | PDF | References | Request permissions

Usefulness of automated fragmented red blood cell percentage in the diagnosis of paediatric haemolytic uraemic syndrome

Srinivasavaradan Govindarajan, Prateek Bhatia, Lesa Dawman, Karalanglin Tiewsoh

Pages: 40-43 | First Published: 27 August 2020

Abstract | Full text | PDF | References | Request permissions

Peripheral blood morphology review and diagnostic proficiency evaluation by a new Spanish EQAS during the period 2011-2019

José Alcaraz-Quiles, Ángel Molina, Javier Laguna, María Rodríguez-García, Gabriela Gutiérrez, José Luis Bedini, Anna Merino

Pages: 44-51 | First Published: 01 September 2020

Abstract | Full text | PDF | References | Request permissions

The HemoScreen hematology point-of-care device is suitable for rapid evaluation of acute leukemia patients

Dår Kristian Kur, Danny Thøgersen, Lars Kjeldsen, Lennart Friis-Hansen

Pages: 52-60 | First Published: 07 September 2020

Abstract | Full text | PDF | References | Request permissions

Flow cytometry

Evaluation of the BD Stem Cell Enumeration Kit on the BD FACSCanto II flow cytometer using BD FACSCANTO CLINICAL and BD FACSDIVA software

Vladimira Rimac, Ines Bojanić, Koraljka Gojčeta, Branka Golubić Ćepulić

Pages: 61-67 | First Published: 15 September 2020

Abstract | Full text | PDF | References | Request permissions

Flow cytometry in detection of Nucleophosmin 1 mutation in acute myeloid leukemia patients: A reproducible tertiary hospital experience

Rasha Abd El-Rahman El-Gamal, Azza El-Sayed Hashem, Deena Mohamed Habashy, Menna Allah Zakareya Abou Elwafa, Noha Hussein Boshnak

Pages: 68-75 | First Published: 27 August 2020

Abstract | Full text | PDF | References | Request permissions

A study to compare Hematopoietic Progenitor Cell count determined on a nextgeneration automated cell counter with flow cytometric CD34 count in peripheral blood and the harvested peripheral blood stem cell graft from autologous and allogenic donors

Shruti Mishra, Uday Kulkarni, Nitty Mathews, Ramya V, Sukesh Ch. Nair, Biju George, Joy J. Mammen

Pages: 76-83 | First Published: 14 September 2020

Abstract | Full text | PDF | References | Request permissions

Dynamic prediction of relapse in patients with acute leukemias after allogeneic transplantation: Joint model for minimal residual disease

Aijie Huang, Qi Chen, Yang Fei, Ziwei Wang, Xiong Ni, Lei Gao, Li Chen, Jie Chen, Weiping Zhang, Jianmin Yang, Jianmin Wang, Xiaoxia Hu

Pages: 84-92 | First Published: 03 September 2020

Abstract | Full text | PDF | References | Request permissions

Hematopathology and molecular hematology

Seasonal variations in hematological disorders: A 10-year single-center experience

Jawad Hassan, Syed Omair Adil, Zeeshan Haider, Sidra Zaheer, Nida Anwar, Muhammad Nadeem, Saqib Hussain Ansari, Tahir Shamsi

Pages: 93-98 | First Published: 15 September 2020

Abstract | Full text | PDF | References | Request permissions

High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome

Linlin Gao, Azhar Saeed, Shivani Golem, Da Zhang, Janet Woodroof, Joseph McGuirk, Siddhartha Ganguly, Sunil Abhyankar, Tara L. Lin, Wei Cui

Pages: 99-109 | First Published: 19 August 2020

Abstract | Full text | PDF | References | Request permissions

COVID-19

☆ Free Access

Relationship of D-dimer with severity and mortality in SARS-CoV-2 patients : A metaanalysis

Johanes Nugroho, Ardyan Wardhana, Irma Maghfirah, Eka Prasetya Budi Mulia, Dita Aulia Rachmi, Maya Qurota A'yun, Imanita Septianda

Pages: 110-115 | First Published: 15 September 2020

Abstract | Full text | PDF | References | Request permissions

☐ Free Access

Interest of the cellular population data analysis as an aid in the early diagnosis of SARS-CoV-2 infection

Marc Vasse, Marie-Christine Ballester, Degnile Ayaka, Dmitry Sukhachev, Frédérique Delcominette, Florence Habarou, Emilie Jolly, Elena Sukhacheva, Tiffany Pascreau, Éric Farfour

Pages: 116-122 | First Published: 19 August 2020

Abstract | Full text | PDF | References | Request permissions

Free Access

Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays

Danielle White, Stephen MacDonald, Tara Edwards, Chris Bridgeman, Megan Hayman, Megan Sharp, Sally Cox-Morton, Emily Duff, Swati Mahajan, Chloe Moore, Melissa Kirk, Richard Williams, Martin Besser, Will Thomas

Pages: 123-130 | First Published: 05 September 2020

Abstract | Full text | PDF | References | Request permissions

Hemostasis and Thrombosis

Impact of variation in reagent combinations for one-stage clotting assay on assay discrepancy in nonsevere haemophilia A

Atsuo Suzuki, Nobuaki Suzuki, Takeshi Kanematsu, Shuichi Okamoto, Shogo Tamura, Ryosuke Kikuchi, Akira Katsumi, Hitoshi Kiyoi, Tetsuhito Kojima, Tadashi Matsushita

Pages: 131-138 | First Published: 11 September 2020

Abstract | Full text | PDF | References | Request permissions

C-reactive protein-induced activated partial thromboplastin time prolongation in heparinized samples is attenuated by elevated factor VIII

Vadim Kostousov, Sridevi Devaraj, Karen Bruzdoski, Lisa Hensch, Shiu-Ki Hui, Jun Teruya

Pages: 139-142 | First Published: 19 August 2020

Abstract | Full text | PDF | References | Request permissions

LETTERS TO THE EDITOR

Alterations in leucocyte cell population data in bacteraemia: A study from a tertiary care hospital in India

Roshini Shekhar, Swati Pai, Vishrut K. Srinivasan, Venkatappa Srinivas, Ranjeeta Adhikary, Malavalli Venkatesh Bhavana

Pages: e1-e4 | First Published: 26 August 2020

First Page | Full text | PDF | References | Request permissions

Free Access

Reduced activity of B lymphocytes, recognised by Sysmex XN-2000™ haematology analyser, predicts mortality in patients with coronavirus disease 2019

Roberta Rolla, Matteo Vidali, Chiara Puricelli, Anna Maria Scotta, Anita Pedrinelli, Patrizia Pergolini, Mario Pirisi, Umberto Dianzani, Cristina Rigamonti

Pages: e5-e8 | First Published: 07 September 2020

First Page | Full text | PDF | References | Request permissions

Validation of the Mission Point-of-care device for haemoglobin measurement

Susan Louw, Anthony Leland Hamilton Mayne, Yuen On Wan, Elizabeth Mayne

Pages: e9-e11 | First Published: 03 October 2020

Full text | PDF | References | Request permissions

Red blood cell and reticulocyte-related parameters in adult patients with β-thalassemia diseases

Chaicharoen Tantanate

Pages: e12-e16 | First Published: 15 September 2020

First Page | Full text | PDF | References | Request permissions

☆ Free Access

Lupus anticoagulant in patients with COVID-19

Ariella Tvito, Eli Ben-Chetrit, Frederic Shmuel Zimmerman, Elad Asher, Yigal Helviz

Pages: e17-e18 | First Published: 11 September 2020

Full text | PDF | References | Request permissions

Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

Celalettin Ustun, Elizabeth A. Morgan, Ethan M Ritz, Hanne Vestergaard, Sheeja Pullarkat, Philip M. Kluin, Robert Ohgami, Linda B. Baughn, Young Kim, Nam K. Ku, David Czuchlewski, Michael Boe Møller, Ana-Iris Schiefer, Krzysztof Mrózek, Hans-Peter Horny, Tracy I. George, Thomas Kielsgaard Kristensen, Todd Beck, Sunita Nathan, Cecilia Arana Yi, Cecilia Yeung, Vinod Pullarkat, Jason Gotlib, Cem Akin, Jessica Kohlschmidt, Amandeep Salhotra, Lori Soma, Dong Chen, Se Y. Han, Christina Cho, Wolfgang Sperr, Sigurd Broesby-Olsen, Michael A. Linden, Michelle Dolan, Gregor Hoermann, Jason L Hornick, Clara Bloomfield, Ryo Nakamura, H. Joachim Deeg, Mark R. Litzow, Gautam Borthakur, Daniel Weisdorf, Gerwin Huls, Miguel-Angel Perales, Peter Valent, Guido Marcucci

Pages: e19-e25 | First Published: 14 September 2020

First Page | Full text | PDF | References | Request permissions

Utility of cleaved lymphocytes from peripheral blood smear in the diagnosis of pertussis

Ruimu Zhang, Hongmei Wang, Chi Li, Yunsheng Chen, Gang Xu, Jikui Deng

Pages: e26-e27 | First Published: 17 September 2020

Full text | PDF | References | Request permissions

Free Access

Immune thrombocytopenic purpura after COVID-19 infection

Michael Levraut, Marie Ottavi, Sarah Lechtman, Véronique Mondain, Pierre-Yves Jeandel

Pages: e28-e30 | First Published: 20 September 2020

Full text | PDF | References | Request permissions

Evaluation of Xpert[®] BCR-ABL Ultra for the confirmation of *BCR-ABL1* international scale conversion factors for the molecular monitoring of chronic myeloid leukaemia

Katherine M. Dominy, Iris M. Simon, Jamshid Sorouri-Khorashad

Pages: e31-e34 | First Published: 29 September 2020

First Page | Full text | PDF | References | Request permissions

Platelet count in sodium citrate-anticoagulated whole blood: Comparison to EDTA-anticoagulated results and stability over time

Darlean Weber, Megan O. Nakashima

Pages: e35-e37 | First Published: 13 October 2020

Full text | PDF | References | Request permissions

Free Access

Lymphopenia in critically ill COVID-19 patients: A predictor factor of severity and mortality

Amra Ziadi, Abdelhamid Hachimi, Brahim Admou, Raja Hazime, Imane Brahim, Fouzia Douirek, Youssef Zarrouki, Ahmed R. El Adib, Said Younous, Abdenasser M. Samkaoui

Pages: e38-e40 | First Published: 30 September 2020

Full text | PDF | References | Request permissions

Plasma vs serum as test sample for the chemiluminescent AcuStar HemosIL HIT- $IgG_{(PF4-H)}$ assay

Emmanuel J. Favaloro, Soma Mohammed

Pages: e41-e44 | First Published: 30 September 2020

First Page | Full text | PDF | References | Request permissions

☐ Free Access

COVID-19 and the ABO blood group in pregnancy: A tale of two multiethnic cities

Irshad Ahmed, Lauren Quinn, Bee K. Tan

Pages: e45-e47 | First Published: 30 September 2020

Full text | PDF | References | Request permissions

Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing

Jonathan Evrard, Michaël Hardy, Jean-Michel Dogné, Sarah Lessire, Vincent Maloteau, François Mullier, Jonathan Douxfils

Pages: e48-e51 | First Published: 10 October 2020

First Page | Full text | PDF | References | Request permissions

Bilirubin crystals were detected in peripheral blood neutrophils in newborn with sepsis and G6PD deficiency

Daolian Huang, Huichun Tong

Pages: e52-e53 | First Published: 13 December 2020

Full text | PDF | References | Request permissions

Tools

- Submit an Article
- **Browse free sample issue**
- Get content alerts
- Subscribe to this journal

International Society of Laboratory Hematology



More from this journal

New Books in Hematology & Transfusion Search Engine Optimization: For Authors

DIVERSITY in Research Jobs

Please contact us to see your job listed here

Medical Laboratory Scientist Sr - Hematology - Full-Time - DAY shift - \$5,000 Sign-On Bonus Richmond County, VA

\$5,000 Sign-On Bonus! The Medical Technologist Senior (MT Sr.) will perform the duties of a technical specialist in the Laboratory. Technically, th...

Employer: Virginia Commonwealth University Health System

Apply for this job

Head, Hematology and Oncology Cell Therapy Field Medical

Collegeville, Pennsylvania | Competitive

Site Name: Upper Providence Posted Date: Mar 9 2022 Head, Hematology and Opcology Coll Thorapy Field Medical Are you interested in a highly visible



About Wiley Online Library

Privacy Policy
Terms of Use
About Cookies
Manage Cookies
Accessibility
Wiley Research DE&I Statement and Publishing Policies

Help & Support

Contact Us
Training and Support
DMCA & Reporting Piracy

Opportunities

Subscription Agents
Advertisers & Corporate Partners

Connect with Wiley

The Wiley Network Wiley Press Room



International Journal of Laboratory Hematology

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX			
United Kingdom Universities and research institutions in United Kingdom	Biochemistry, Genetics and Molecular Biology Clinical Biochemistry Medicine Biochemistry (medical) Hematology Medicine (miscellaneous)	Wiley-Blackwell Publishing Ltd	55			
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION			
Journals	17515521, 1751553X	2007-2020	Homepage How to publish in this journal IJLHoffice@wiley.com			
SCOPE						
The International Journal of Laboratory Hematology provides a forum for the communication of new developments, research topics and the practice of laboratory haematology. The journal						

The International Journal of Laboratory Hematology provides a forum for the communication of new developments, research topics and the practice of laboratory haematology. The journal publishes invited reviews, full length original articles, and correspondence. The International Journal of Laboratory Hematology is the official journal of the International Society for Laboratory Hematology, which addresses the following sub-disciplines: cellular analysis, flow cytometry, haemostasis and thrombosis, molecular diagnostics, haematology informatics, haematology informatics, point of care testing, standards and guidelines. The journal was launched in 2006 as the successor to Clinical and Laboratory Hematology, which was first published in 1979. An active and positive editorial policy ensures that work of a high scientific standard is reported, in order to bridge the gap between practical and academic aspects of laboratory haematology.


 $\begin{picture}(100,0) \put(0,0){\line(0,0){100}} \put(0,0){\line(0,0){10$

Quartiles

1 of 3 4/22/2022, 10:42 AM

options :

FIND SIMILAR JOURNALS 2



Metrics based on Scopus® data as of April 2021

Name
Email (will not be published)

2 of 3 4/22/2022, 10:42 AM



Source details

International Journal of Laboratory Hematology

Formerly known as: Clinical and Laboratory Haematology

Scopus coverage years: from 2007 to Present

Publisher: Wiley-Blackwell

ISSN: 1751-5521 E-ISSN: 1751-553X

Subject area: (Medicine: Hematology) (Medicine: Biochemistry (medical))

Biochemistry, Genetics and Molecular Biology: Clinical Biochemistry

Source type: Journal

CiteScore CiteScore rank & trend Scopus content coverage

CiteScore ₂₀₂₀ ~

 $3.4 = \frac{1,537 \text{ Citations } 2017 - 2020}{454 \text{ Documents } 2017 - 2020}$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ①

 $3.7 = \frac{2,153 \text{ Citations to date}}{580 \text{ Documents to date}}$

Last updated on 06 April, 2022 • Updated monthly

CiteScore rank 2020 ①

Category	Rank Percentile	·
Medicine Hematology	#59/123	52nd
Medicine Biochemistry (medical)	#30/54	45th
Biochemistry, Genetics and Molecular Biology	#73/113	35th

View CiteScore methodology \gt CiteScore FAQ \gt Add CiteScore to your site $c^{\mathfrak{D}}$

CiteScore 2020 **3.4**

①

(i)

SJR 2020 **0.705**

SNIP 2020

1.105

About Scopus

What is Scopus

Content coverage

Scopus blog

Scopus API

Privacy matters

Language

日本語に切り替える

切换到简体中文

切換到繁體中文

Русский язык

Customer Service

Help

Tutorials

Contact us

ELSEVIER

Terms and conditions \supset Privacy policy \supset

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

